urovestВестник урологииUrology Herald2308-6424Rostov State Medical University10.21886/2308-6424-2020-8-2-50-54urovest-330Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEWS ARTICLEПостфинастеридный синдром: наши представления сегодняPost-finasteride syndrome: our current knowledgehttps://orcid.org/0000-0002-6474-3546ГалушкинА. А.GalushkinA. A.

Александр Алексеевич Галушкин – к.м.н; научный медицинский эксперт в области урологии, антимикробной и химиотерапии компании 

тел.: +7 (988) 531-13-79

Aleksandr A. Galushkin – M.D., Cand.Sc.(M); Medical Scientific Expert for Urology and Antiinfectives

Medical Department

alexander.a.galushkin@gsk.comhttps://orcid.org/0000-0001-9319-864XЛихихД. Г.LikhikhD. G.

Дмитрий Геннадьевич Лихих – к.м.н.; медицинский менеджер, направление урология

Dmitriу G. Likhikh ‒ M.D., Cand.Sc.(M); Medical Affairs Manager, Urology Portfolio

Medical Department

dmitry.x.likhikh@gsk.comhttps://orcid.org/0000-0002-1710-0169КоганМ. И.KoganM. I.

Михаил Иосифович Коган – Заслуженный деятель науки РФ, д.м.н., профессор; заведующий кафедрой урологии и репродуктивного здоровья человека (с курсом детской урологии-андрологии)

Mikhail I. Kogan – Honored Scientist of Russian Federation, M.D., Dr.Sc.(M), Full Prof.; Head, Dept. of Urology and Human Reproductive Health (with the Pediatric Urology and Andrology Сourse)

dept_kogan@mail.ruАО «ГлаксоСмитКляйн Трейдинг»РоссияGlaxoSmithKline TradingRussian FederationФГБОУ ВО «Ростовский государственный медицинский университет» Минздрава РоссииРоссияRostov State Medical UniversityRussian Federation202030062020825054Copyright © Галушкин А.А., Лихих Д.Г., Коган М.И., 20202020Галушкин А.А., Лихих Д.Г., Коган М.И.Galushkin A.A., Likhikh D.G., Kogan M.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.urovest.ru/jour/article/view/330

Ингибиторы 5-α редуктазы являются эффективной и часто используемой терапией при доброкачественной гиперплазии предстательной железы. Однако возникают вопросы, связанные с профилем безопасности данной группы препаратов. Постфинастеридный синдром — противоречивый синдром, связанный с совокупностью сексуальных, соматических и психических симптомов, развивающийся во время или после прекращения прием финастерида и сохраняющийся после его отмены. Учитывая общность механизмов действия финастерида и дутастерида, можно предположить, что термин «постфинастеридный синдром» распространяется на всю группу ингибиторов 5-α редуктазы. На сегодняшний день нет однозначного понимания причин и патофизиологических механизмов развития этого состояния. Неоднозначные результаты завершённых исследований по изучению психологических, метаболических и сексуальных нарушений при приёме ингибиторов 5-α редуктазы говорят о возможности рассмотрения данного феномена как одного из представителей «загадочных болезней», носящих исключительно психосоциальную природу. Кроме того, отсутствие понимания причин и механизмов посфинастеридного синдрома, демонстрируют необходимость проведения дополнительных исследований в этом направлении с учётом погрешностей предыдущих работ.

Конфликт интересов. Александр A. Галушкин и Дмитрий Г. Лихих являются сотрудниками фармацевтической компании АО «ГлаксоСмитКляйн Трейдинг», Михаил И. Коган заявляет об отсутствии конфликта интересов.

5-α reductase inhibitors are effective and commonly used medications for the treatment of benign prostatic hyperplasia. However, there are some questions about the safety of such medications. A post-finasteride syndrome is a controversial syndrome associated with a constellation of sexual, physical, and psychological symptoms that develop during or after finasteride exposure and persist after discontinuation. Finasteride and dutasteride have the same mechanism of action and we can suppose that the term «post-finasteride syndrome» may apply to the whole group of 5-alfa reductase inhibitors. Nowadays, reasons and development mechanisms of this syndrome are unclear. The results of studies on sexual, physical, and psychological disorders have shown mixed results. Some experts attribute post-finasteride syndrome to a group of «mysterious diseases» based on psychosocial factors. Also, we need new studies with better design because reasons and development mechanisms of this syndrome are unclear.

Aleksandr A. Galushkin and Dmitriу G. Likhikh are employees GlaxoSmithKline Trading, Michael I. Kogan declares no conflict of interest.

постфинастеридный синдромингибиторы 5-альфа редуктазыпсихические расстройстванарушения метаболизмасексуальная дисфункцияpost-finasteride syndrome5-alfa reductase inhibitorspsychological disordersmetabolic disorderssexual dysfunctionReferencesGray SL, Semla TP. Post-finasteride syndrome. BMJ. 2019;366:l5047. https://doi.org/10.1136/bmj.l5047Gray SL, Semla TP. Post-finasteride syndrome. BMJ. 2019;366:l5047. https://doi.org/10.1136/bmj.l5047Trüeb RM, Régnier A, Dutra Rezende H, Gavazzoni Dias MFR. Post-Finasteride Syndrome: An Induced Delusional Disorder with the Potential of a Mass Psychogenic Illness? Skin Appendage Disord. 2019;5(5):320‒326. https://doi.org/10.1159/000497362Trüeb RM, Régnier A, Dutra Rezende H, Gavazzoni Dias MFR. Post-Finasteride Syndrome: An Induced Delusional Disorder with the Potential of a Mass Psychogenic Illness? Skin Appendage Disord. 2019;5(5):320‒326. https://doi.org/10.1159/000497362Melcangi RC, Santi D, Spezzano R, Grimoldi M, Tabacchi T, Fusco ML, Diviccaro S, Giatti S, Carrà G, Caruso D, Simoni M, Cavaletti G. Neuroactive steroid levels and psychiatric and andrological features in post-finasteride patients. J Steroid Biochem Mol Biol. 2017;171:229‒235. https://doi. org/10.1016/j.jsbmb.2017.04.003Melcangi RC, Santi D, Spezzano R, Grimoldi M, Tabacchi T, Fusco ML, Diviccaro S, Giatti S, Carrà G, Caruso D, Simoni M, Cavaletti G. Neuroactive steroid levels and psychiatric and andrological features in post-finasteride patients. J Steroid Biochem Mol Biol. 2017;171:229‒235. https://doi. org/10.1016/j.jsbmb.2017.04.003Melcangi RC, Caruso D, Abbiati F, Giatti S, Calabrese D, Piazza F, Cavaletti G. Neuroactive steroid levels are modified in cerebrospinal fluid and plasma of postfinasteride patients showing persistent sexual side effects and anxious/depressive symptomatology. J Sex Med. 2013;10(10):2598‒2603. https://doi.org/10.1111/jsm.12269Melcangi RC, Caruso D, Abbiati F, Giatti S, Calabrese D, Piazza F, Cavaletti G. Neuroactive steroid levels are modified in cerebrospinal fluid and plasma of postfinasteride patients showing persistent sexual side effects and anxious/depressive symptomatology. J Sex Med. 2013;10(10):2598‒2603. https://doi.org/10.1111/jsm.12269Caruso D, Abbiati F, Giatti S, Romano S, Fusco L, Cavaletti G, Melcangi RC. Patients treated for male pattern hair with finasteride show, after discontinuation of the drug, altered levels of neuroactive steroids in cerebrospinal fluid and plasma. J Steroid Biochem Mol Biol. 2015;146:74‒79. https://doi.org/10.1016/j.jsbmb.2014.03.012Caruso D, Abbiati F, Giatti S, Romano S, Fusco L, Cavaletti G, Melcangi RC. Patients treated for male pattern hair with finasteride show, after discontinuation of the drug, altered levels of neuroactive steroids in cerebrospinal fluid and plasma. J Steroid Biochem Mol Biol. 2015;146:74‒79. https://doi.org/10.1016/j.jsbmb.2014.03.012Giatti S, Diviccaro S, Panzica G, Melcangi RC. Post-finasteride syndrome and post-SSRI sexual dysfunction: two sides of the same coin? Endocrine. 2018;61(2):180‒193. https://doi.org/10.1007/s12020-018-1593-5Giatti S, Diviccaro S, Panzica G, Melcangi RC. Post-finasteride syndrome and post-SSRI sexual dysfunction: two sides of the same coin? Endocrine. 2018;61(2):180‒193. https://doi.org/10.1007/s12020-018-1593-5Soggiu A, Piras C, Greco V, Devoto P, Urbani A, Calzetta L, Bortolato M, Roncada P. Exploring the neural mechanisms of finasteride: a proteomic analysis in the nucleus accumbens. Psychoneuroendocrinology. 2016;74:387‒396. https://doi.org/10.1016/j.psyneuen.2016.10.001Soggiu A, Piras C, Greco V, Devoto P, Urbani A, Calzetta L, Bortolato M, Roncada P. Exploring the neural mechanisms of finasteride: a proteomic analysis in the nucleus accumbens. Psychoneuroendocrinology. 2016;74:387‒396. https://doi.org/10.1016/j.psyneuen.2016.10.001Welk B, McArthur E, Ordon M, Anderson KK, Hayward J, Dixon S. Association of Suicidality and Depression With 5α-Reductase Inhibitors. JAMA Intern Med. 2017;177(5):683‒691. https://doi.org/10.1001/jamainternmed.2017.0089Welk B, McArthur E, Ordon M, Anderson KK, Hayward J, Dixon S. Association of Suicidality and Depression With 5α-Reductase Inhibitors. JAMA Intern Med. 2017;177(5):683‒691. https://doi.org/10.1001/jamainternmed.2017.0089Wei L, Lai EC, Kao-Yang YH, Walker BR, MacDonald TM, Andrew R. Incidence of type 2 diabetes mellitus in men receiving steroid 5α-reductase inhibitors: a populationbased cohort study. BMJ. 2019;365:l1204. https://doi.org/10.1136/bmj.l1204Wei L, Lai EC, Kao-Yang YH, Walker BR, MacDonald TM, Andrew R. Incidence of type 2 diabetes mellitus in men receiving steroid 5α-reductase inhibitors: a populationbased cohort study. BMJ. 2019;365:l1204. https://doi.org/10.1136/bmj.l1204Hagberg KW, Divan HA, Persson R, Nickel JC, Jick SS. Risk of erectile dysfunction associated with the use of 5-α reductase inhibitors for benign prostatic hyperplasia or alopecia: population-based studies using the Clinical Practice Research Datalink. BMJ. 2016;354:i4823. https://doi.org/10.1136/bmj.i4823Hagberg KW, Divan HA, Persson R, Nickel JC, Jick SS. Risk of erectile dysfunction associated with the use of 5-α reductase inhibitors for benign prostatic hyperplasia or alopecia: population-based studies using the Clinical Practice Research Datalink. BMJ. 2016;354:i4823. https://doi.org/10.1136/bmj.i4823Roehrborn CG, Manyak MJ, Palacios-Moreno JM, Wilson TH, Roos EPM, Santos JC, Karanastasis D, Plastino J, Giuliano F, Rosen RC. A prospective randomised placebocontrolled study of the impact of dutasteride/tamsulosin combination therapy on sexual function domains in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). BJU Int. 2018;121(4):647‒658. https://doi.org/10.1111/bju.14057Roehrborn CG, Manyak MJ, Palacios-Moreno JM, Wilson TH, Roos EPM, Santos JC, Karanastasis D, Plastino J, Giuliano F, Rosen RC. A prospective randomised placebocontrolled study of the impact of dutasteride/tamsulosin combination therapy on sexual function domains in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). BJU Int. 2018;121(4):647‒658. https://doi.org/10.1111/bju.14057Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215‒224. https://doi.org/10.1056/NEJMoa030660Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215‒224. https://doi.org/10.1056/NEJMoa030660Moinpour CM, Darke AK, Donaldson GW, Cespedes D, Johnson CR, Ganz PA, Patrick DL, Ware JE Jr, Shumaker SA, Meyskens FL, Thompson IM Jr. Health-related qualityof-life findings for the prostate cancer prevention trial. J Natl Cancer Inst. 2012;104(18):1373‒1385. https://doi.org/10.1093/jnci/djs359Moinpour CM, Darke AK, Donaldson GW, Cespedes D, Johnson CR, Ganz PA, Patrick DL, Ware JE Jr, Shumaker SA, Meyskens FL, Thompson IM Jr. Health-related qualityof-life findings for the prostate cancer prevention trial. J Natl Cancer Inst. 2012;104(18):1373‒1385. https://doi.org/10.1093/jnci/djs359Unger JM, Till C, Thompson IM Jr, Tangen CM, Goodman PJ, Wright JD, Barlow WE, Ramsey SD, Minasian LM, Hershman DL. Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2016;108(12):djw168. https://doi.org/10.1093/jnci/djw168Unger JM, Till C, Thompson IM Jr, Tangen CM, Goodman PJ, Wright JD, Barlow WE, Ramsey SD, Minasian LM, Hershman DL. Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2016;108(12):djw168. https://doi.org/10.1093/jnci/djw168Pietrzyk B, Olszanecka-Glinianowicz M, Owczarek A, Gabryelewicz T, Almgren-Rachtan A, Prajsner A, Chudek J. Depressive symptoms in patients diagnosed with benign prostatic hyperplasia. Int Urol Nephrol. 2015;47(3):431‒440. https://doi.org/10.1007/s11255-015-0920-5Pietrzyk B, Olszanecka-Glinianowicz M, Owczarek A, Gabryelewicz T, Almgren-Rachtan A, Prajsner A, Chudek J. Depressive symptoms in patients diagnosed with benign prostatic hyperplasia. Int Urol Nephrol. 2015;47(3):431‒440. https://doi.org/10.1007/s11255-015-0920-5Altomare G, Capella GL. Depression circumstantially related to the administration of finasteride for androgenetic alopecia. J Dermatol. 2002;29(10):665‒669. https://doi.org/10.1111/j.1346-8138.2002.tb00200.xAltomare G, Capella GL. Depression circumstantially related to the administration of finasteride for androgenetic alopecia. J Dermatol. 2002;29(10):665‒669. https://doi.org/10.1111/j.1346-8138.2002.tb00200.xIrwig MS. Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects. J Clin Psychiatry. 2012;73(9):1220‒1223. https://doi.org/10.4088/JCP.12m07887Irwig MS. Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects. J Clin Psychiatry. 2012;73(9):1220‒1223. https://doi.org/10.4088/JCP.12m07887Traish A, Haider KS, Doros G, Haider A. Long-term dutasteride therapy in men with benign prostatic hyperplasia alter glucose and lipid profiles and increases the severity of erectile dysfunction. Horm Mol Biol Clin Investig. 2017;30(3):/j/ hmbci.2017.30.issue-3/hmbci-2017-0015/hmbci-2017-0015. xml. https://doi.org/10.1515/hmbci-2017-0015Traish A, Haider KS, Doros G, Haider A. Long-term dutasteride therapy in men with benign prostatic hyperplasia alter glucose and lipid profiles and increases the severity of erectile dysfunction. Horm Mol Biol Clin Investig. 2017;30(3):/j/ hmbci.2017.30.issue-3/hmbci-2017-0015/hmbci-2017-0015. xml. https://doi.org/10.1515/hmbci-2017-0015Livingstone DE, Barat P, Di Rollo EM, Rees GA, Weldin BA, Rog-Zielinska EA, MacFarlane DP, Walker BR, Andrew R. 5α-Reductase type 1 deficiency or inhibition predisposes to insulin resistance, hepatic steatosis, and liver fibrosis in rodents. Diabetes. 2015;64(2):447‒458. https://doi.org/10.2337/db14-0249Livingstone DE, Barat P, Di Rollo EM, Rees GA, Weldin BA, Rog-Zielinska EA, MacFarlane DP, Walker BR, Andrew R. 5α-Reductase type 1 deficiency or inhibition predisposes to insulin resistance, hepatic steatosis, and liver fibrosis in rodents. Diabetes. 2015;64(2):447‒458. https://doi.org/10.2337/db14-0249Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Nandy I, Morrill BB, Gagnier RP, Montorsi F; CombAT Study Group. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57(1):123‒131. https://doi.org/10.1016/j.eururo.2009.09.035Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Nandy I, Morrill BB, Gagnier RP, Montorsi F; CombAT Study Group. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57(1):123‒131. https://doi.org/10.1016/j.eururo.2009.09.035Ganzer CA, Jacobs AR. Emotional Consequences of Finasteride: Fool’s Gold. Am J Men’s Health. 2018;12(1):90‒95. https://doi.org/10.1177/1557988316631624Ganzer CA, Jacobs AR. Emotional Consequences of Finasteride: Fool’s Gold. Am J Men’s Health. 2018;12(1):90‒95. https://doi.org/10.1177/1557988316631624

The authors declare that there are no conflicts of interest present.